e-SPACE Cardio-Renal-Metabolic 2024
Published: 29 March 2024
-
Views:
508
-
Likes:
7
-
Views:
508
-
Likes:
7
-
Up Next -
59m 47s
-
57m 21s
-
1h 7sPart 1 | Session 6 Plenary Session 5 – CRM disease: epidemiology and pathophysiology
-
54m 56sPart 2 | Session 1 Plenary Session 6 – Anaemia and iron deficiency
-
16m 6s
-
1h 10s
-
1h 8m 49sPart 2 | Session 4 Plenary Session 8 – Early intervention and intensive management
-
27m 17sPart 2 | Session 5 Effects of GLP- 1RA on kidney outcomes in CKD and T2D
-
1h 3m 47sPart 2 | Session 6 Plenary Session 9 – Precision medicine in CRM
-
1h 6sPart 1 | Session 1 Plenary Session 1 – Multidisciplinary implementation strategies Gerasimos Filippatos, Manisha Sahay, Gianluigi Savarese, Francesco Cosentino, Sam Seidu
-
28m 56sPart 1 | Session 2 Keynote Session – KDIGO guideline updates 2024 Paul Stevens
Overview
KDIGO and Translational Medicine Academy (TMA) in partnership with Radcliffe Cardiology were delighted to announce the return of e-SPACE Cardio-Renal-Metabolic (CRM) 2024.
A thoughtfully curated programme supported the exploration of how leading experts, in cardiology, nephrology and diabetology, treat the interrelated diseases.
This event once again brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
Related sessions to e-SPACE Cardio-Renal-Metabolic 2024:
Learning Objectives
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease and obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
Target Audience
- Cardiologists
- Nephrologists
- Diabetologists
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One
Part 2
Day Two
Faculty Biographies
Intissar Haddiya
Nephrologist
Prof Intissar Haddiya is a Nephrologist at Mohamed First University, Oujda, MA.
Prof Haddiya's interests include hypertension, kidney disease, dialysis, kidney donation and transplant.
Lars H Lund
Associate Professor and Senior Consultant
Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions.
Dr Lars Lund is an Editorial Board member of Cardiac Failure Review.
Marco Metra
Professor
Marco Metra is Full Professor of Cardiology and Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, and Editor-in-Chief of the European Journal of Heart Failure and Senior Consulting Editor of the European Heart Journal.
Prof Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with heart failure. His research is focused on heart failure with, as main areas of interest, β-blocker therapy and, more recently, the assessment and treatment of the patients with acute heart failure.
He has co-chaired with Prof. Teerlink, San Francisco, CA, the phase IIB Pre-RELAX-AHF and the phase III RELAX-AHF randomized placebo controlled trials in patients with acute heart failure and is chairing the current RELAX-AHF-2 trial, which has as primary end-points the effects of serelaxin on the 180-days mortality and on in-hospital worsening heart…
Nikolaus Marx
Professor of Medicine
Prof Nikolaus Marx is a Professor of Medicine / Cardiology at RWTH University Hospital Aachen, Aachen, DE.
Prof Marx's interests include cardiovascular disease in patients with comorbidities including diabetes and chronic kidney disease.
Peter Rossing
Clinical Professor
Prof Peter Rossing is a Clinical Professor at University of Copenhagen, Copenhagen, DK.
His interests include complications in diabetes with focus on renal and cardiovascular complications.
He has been involved in several intervention studies in patients with overt diabetic nephropathy aiming at improving the prognosis.
Prof Rossing is past president of the Danish Endocrine Society, and of the European Diabetic Nephropathy Study group and chairman of the Danish National Diabetes Registry.
Giuseppe Rosano
Consultant Cardiologist and Professor of Cardiology (Hon)
Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.
Prof Rosano's areas of expertise include heart failure, cardiac metabolism, cardiovascular pharmacology and pharmacotherapy, heart disease in women and cardiovascular effects of sex hormones. He has a specific interest in chronic coronary syndromes and in angina with normal coronary arteries.
Prof Rosano has been core member of the Cardiovascular Working Party of the European Medicines Agency and member of the Pricing and Reimbursement Committee of the Italian…
Comments